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Abstract: Methacrylated gellan gum (GGMA) formulation is
proposed as a second-generation hydrogel for controlled
delivery of cartilage-forming cells into focal chondral
lesions, allowing immediate in situ retention of cells and 3D
filling of lesion volume, such approach deemed compatible
with an arthroscopic procedure. Formulation optimization
was carried out in vitro using chondrocytes and adipose
mesenchymal stromal/stem cells (ASCs). A proof-of-concept
in vivo study was conducted using a rabbit model with
induced chondral lesions. Outcomes were compared with
microfracture or non-treated control. Three grading scores
were used to evaluate tissue repair after 8 weeks by macro-
scopic, histological and immunohistochemical analysis.
Intense collagen type II and low collagen type I gene and
protein expression were achieved in vitro by the
ASC1GGMA formulation, in light with development of
healthy chondral tissue. In vivo, this formulation promoted
significantly superior de novo cartilage formation compared
with the non-treated group. Maintenance of chondral height
and integration with native tissue was further accomplished.
The physicochemical properties of the proposed GGMA
hydrogel exhibited highly favorable characteristics and bio-
logical performance both in vitro and in vivo, positioning
itself as an attractive xeno-free biomaterial to be used with
chondrogenic cells for a cost-effective treatment of focal
chondral lesions. VC 2018 Wiley Periodicals, Inc. J Biomed Mater
Res Part A: 106A: 1987–1996, 2018
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INTRODUCTION
Complementary efforts for improving cartilage repair1 have
addressed optimization of combination strategies involving
predominantly autologous articular chondrocytes2,3 for
which decades of performance history have been col-
lected.4–7 Robust long-term outcomes is among its major
advantages,8,9 yet suboptimal cell retention within cartilage
lesion sites has been a concern,10–12 which has driven the
development and marketing of novel scaffolds or matrices
to enhance efﬁcacy of these procedures.12–14 Nonetheless,
most surgical protocols intervene directly on the
subchondral bone either for recruitment of cells or for ﬁxa-
tion of the scaffold, involve additional ﬁxation systems, or
require invasive procedures, such as arthrotomy, to be effec-
tively implanted.15,16
In previous works17–19 gellan gum (GG) has been pro-
posed as new biomaterial for cartilage tissue engineering
applications. Its versatility and efﬁcacy has been demon-
strated for cartilage repair strategies involving both sub-
chondral stimulation and cell transplantation using a rabbit
model.18 Both histological and gene expression outcomes
conﬁrmed the potential of this approach for cartilage repair
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but limitations concerning usability and crosslinking kinetics
have been identiﬁed, which could limit its translation into a
clinical setting. Subsequent work explored alternative syn-
thetic routes to enhance performance of GG hydrogels,
namely the methacrylation of the molecule (GGMA)20–22 for
other biomedical applications. Rational design modiﬁcation
of GG yielded a second-generation GGMA polymer endowed
with improved physicochemical characteristics, including
better solubilization, liquid formulation prior to injection at
room temperature, improved geliﬁcation kinetics, and more
robust mechanical properties of the hydrogel20–22 the latter
being greatly dependant on the crosslinking mechanism. In
an applied perspective, the adoption of an injectable formu-
lation based in GGMA in the context of cartilage repair is
highly attractive, as its solution-state properties make it
potentially compatible with minimally invasive procedures.
Given the positive track-record of the parent GG molecule
on what regards safety and performance, it becomes manda-
tory to quantify the actual beneﬁts of GGMA in the cartilage
repair application context. Understanding physicochemical
performance of GGMA could be explored to simplify the surgi-
cal protocol, to improve delivery and functional commitment
of cells employed, as well as to minimize damage of the sub-
chondral compartment during the surgical protocol. In this
regard, this study aims to comparatively assess the safety and
performance of GG and GGMA by in vitromethods, as well as to
characterize the performance of GGMA hydrogel as vehicle for
delivery and retention of chondrogenic cells within chondral
lesions, by assessing functional development of hyaline carti-
lage tissue in a rabbit model.
On the perspective of functional performance of cells,
the risk of chondrocyte de-differentiation,23 or lack of
potency of the autologous chondrocytes24–26 along the need
for double surgery and prolonged surgical pre-planning, has
inspired the study of alternative cell sources, including mes-
enchymal stromal/stem cells (MSCs) in general, and
adipose-derived stromal/stem cells (ASCs) in particu-
lar.17,18,27 As compared with other MSC sources, adipose tis-
sue can be harvested with reduced morbidity at the donor
site and yields of ASC are considerably high.28 The immuno-
modulatory and anti-inﬂammatory properties of ASC makes
them an especially attractive cell source for development of
off the shelf regenerative medicine treatments.27,29,30
Herein, preliminary screening demonstrated improved
cell viability of ASC within ionic-crosslinked GGMA as com-
pared with photo-crosslinked, therefore favoring further
experimentation with ionically crosslinked GGMA. The best
performing combination was further evaluated for the treat-
ment of focal chondral lesions in a rabbit model, by adopt-
ing a physiologically inspired crosslinking approach devoid
of toxic photo-initiators and electromagnetic radiation sour-
ces, which is highly desirable from both regulatory and sur-
gical protocol perspectives.
MATERIALS AND METHODS
In vitro chondrogenesis
Preparation of puriﬁed GG and GGMA. Commercial GG
(GGc) (Gelzan, Sigma-Aldrich) was puriﬁed according to the
method described by Doner31 with several modiﬁcations.
Brieﬂy, GGc was suspended in distilled water (1% w/V) and
warmed to 608C with stirring. To this solution was added
Amberlite IR-120 (H1 form) (Sigma-Aldrich) until pH 2.5.
The suspension was ﬁltered and aqueous sodium hydroxide
(NaOH, 1 N) was added until pH 8, while stirring. The
resulting solution was ﬁltered and the ﬁltrate poured onto
absolute ethanol (1 L), forming a thick ﬁbrous precipitate.
After 1 h, the precipitate was ﬁltered, washed with absolute
ethanol and dissolved in distilled water. The resulting solu-
tion was transferred to a cellulose membrane (Molecular
weight cut-off (MWCO) 12 kDa) and dialyzed against dis-
tilled water for 3 days. After freezing (–208C) and lyophiliza-
tion, the puriﬁed GG (GGp) was obtained. GGMA, with a
degree of substitution with methacrylate groups between
1.5 and 5% was prepared as follows: GGc was dissolved in
water to give a solution of 1% w/V concentration. Heating
was stopped and the solution pH was adjusted to 8.5 by
NaOH (1 N). Thereupon, excess glycidyl methacrylate was
added in one portion and the methacrylation reaction was
allowed to proceed for 24 h whilst maintaining the solution
pH close to 8.5. Acetone was then added to the reaction
mixture which was allowed to stand for 2 h. The precipitate
was recovered by ﬁltration, dissolved in distilled water and
then placed in a cellulose dialysis membrane (MWCO 12
kDa) and dialyzed against distilled water for 7 days. The
dialyzed solution was then frozen at 2208C and subse-
quently freeze-dried to give GGMA as an amorphous white
solid. For hydrogel preparation, GGp and GGMA powder
were dissolved in deionized water to achieve solutions at
1.25 and 2.5% w/V, respectively. Dissolution was effected at
378C in a water-bath with 100 rpm agitation.
In vitro culture of human cells. Human nasal cartilage
(hNC) was obtained with informed consent, as surgical
waste from a local hospital and further processed for isola-
tion of chondrocytes as described elsewhere.17 Chondro-
cytes where thawed and expanded in DMEM:F12
supplemented with 10% v/v FBS and 1% v/v antibiotic-
antimycotic (Gibco, USA) until passage 3. Human adipose
tissue (hAT) was obtained from liposuction procedures,
after informed consent and medical questionnaire according
to European directives. Collection of adipose samples was
approved by the Institutional Review Board of “Centro Hos-
pitalar de S~ao Jo~ao”, Portugal. Brieﬂy, hAT was washed with
a decontamination solution (Base-128 Alchimia, Italy) and
digested with collagenase (0.4 U/mL, NB6, SERVA, Germany)
for 1 h at 378C with agitation. The stromal vascular fraction
(SVF) was collected after puriﬁcation steps that include
washing, centrifugation and lysis of red blood cells. Human
adipose mesenchymal stromal/stem cells (hASC) were
obtained from SVF by plating and further expansion in low
serum media (MesenPro, Gibco, USA) or xeno-free media
(Fibrolife, Lifeline, USA) until passage 2 or 4. Quality control
included validation of MSC immunophenotype (CD31, CD34,
CD45, CD73, CD90, and CD105, BD Biosciences, USA) char-
acterized by ﬂow cytometry analysis (FACS Canto, FACSDiva
software, antibodies BD Biosciences, USA), and trilineage
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differentiation (StemPro, Gibco, USA) identiﬁed by alizarin
red, oil red O and alcian blue stainings for osteogenesis, adi-
pogenesis and chondrogenesis, respectively.
Preparation of cell-encapsulated hydrogels for in vitro
culture. An initial comparison study was performed to evaluate
comparative performance of GG and GGMA with respect to
hydrogel formation and metabolic activity of encapsulated
hASC. Selected formulations were further used for assessment
of chondrogenesis by hASC or hNC (Fig. 1). Cell suspensions
were prepared in cell culture media and mixed with GG or
GGMA solution in a 2:8 ratio in order to yield a ﬁnal cell density
of 5 3 106 cells/mL and hydrogel concentrations of 1 and 2%
w/V, respectively. Cellular hydrogels of 20 mL volume were
pipetted (with aid of a positive displacement pipette) into wells
of non-adherent cell culture well-plates and covered with cul-
ture media for crosslinking. To induce chondrogenesis of hASC,
serum-free chondrogenic media (StemPro, Gibco, USA) was
used. At speciﬁc time-points (i.e., 0, 7, and 21 days), individual
hydrogels were collected for analysis. The hASC–GGMA combi-
nationwas further scaled to hydrogels of 50 mL volume contain-
ing 103 106 cells/mL and tested for chondrogenesis.
Assessment of in vitro cell viability and chondro-
genesis. Cell metabolic activity was determined at each
time-point by MTS assay (Promega USA) and cell viability
was further microscopically assessed by Live/Dead assay
(calcein AM and propidium iodide [Invitrogen, USA 1 mg/
mL]). For histology and immunohistochemistry (IHC), hydro-
gels were ﬁxed (10% formalin), followed parafﬁn process-
ing. Histochemical staining of glycosaminoglycans (GAGs) by
Safranin O/Fast green and Alcian Blue were performed as
previously described in.17 For IHC, reagents from Vector
Laboratories (UK) were used. Sections were incubated into
recommended antigen retrieval solutions, followed by inhi-
bition of endogenous peroxidases with 0.3% H2O2 and
blocking with normal horse serum. Thereafter, sections
were stained with primary antibody Mouse anti-human
Anti-Collagen I or Mouse anti-human Anti-Collagen II
(Abcam, UK) for 1 h, RT and a diluted biotinylated second-
ary antibody solution (VECTASTAIN Elite ABC kit) for
30 min, RT. Signal development was performed with the
DAB substrate kit. For gene expression analysis, hydrogels
were collected into TRI Reagent (Sigma-Aldrich, USA) and
recommended protocol for RNA extraction from tissues was
followed. Complementary cDNA was obtained by using the
High Capacity cDNA Reverse Transcription Kit. Gene ampliﬁ-
cation was conducted using TaqMan Fast Advanced Master
Mix and TaqMan Gene Expression Assays for Collagen type
II (Hs00264051_m1) and Collagen type I (Hs00164004_m1).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH,
Hs99999905_m1) was chosen as an invariant standard
(housekeeping gene). Quantitative reverse transcription (RT-
qPCR) analysis was carried out with the StepOnePlus Real-
Time PCR System and software (all reagents and equipment
from Applied Biosystems, USA). Results were normalized to
GAPDH and expressed as relative gene expression using the
DDCt method. The expression data were presented as aver-
age values for each group (n536 SD).
In vivo chondrogenesis
Chondral lesion induction and repair in a rabbit
model. The ICRS and ASTM guidelines were followed for a
proof-of-concept (PoC) study in rabbits to assess in vivo
cartilage tissue repair.32,33 All animal procedures were
based upon the “3R’s” policy, approved by the Institutional
Ethical Committee, according to the National authority
Guide for the Care and Use of Laboratory Animals. Skele-
tally mature (12- to 14-weeks old) New Zealand white
rabbits (2.560.25 kg; Charles-River, France, n5 6) were
used for harvesting adipose tissue and subsequent autolo-
gous treatment of focal chondral lesions. Interscapular adi-
pose tissue (10 g) was collected under anesthesia with a
mixture of ketamine hydrochloride (Imalgene, 25 mg/kg
i.m.) and medetomidine hydrochloride (Domitor, 0.3 mg/kg
i.m.). The obtained adipose tissue samples were digested
for 1 h at 378C, 100 rpm with Collagenase NB4 Standard
Grade 0.2 U/mL (Serva, Germany). After complete diges-
tion, cells were cultured in complete media based on alpha
MEM supplemented with 10% v/v FBS and 1% v/v
antibiotic-antimycotic (Gibco, USA), until passage 2. One
week after adipose tissue harvest, surgery was conducted
to create critical chondral defects in the knee for immedi-
ate administration of treatment. Rabbits were anesthetized
as described above and both knees were shaved and disin-
fected. An internal para-patelar incision was made to
expose the knee. The patella was dislocated and two 4-
mm diameter lesions were made in the trochlear grove of
each knee using a biopsy punch. Lesion sites were care-
fully cleaned with a curette to not affect the sub-chondral
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FIGURE 1. Schematic representation of experimental design. Hydrogel
formulations based on GG and its methacrylated derivative (GGMA)
were tested for gelification and cell encapsulation (stage I). Two for-
mulations were selected for in vitro assessment of chondrogenesis
(stage II) using nasal chondrocytes (NC) and ASC. A final formulation
was applied for treatment of focal chondral lesions in an induced rab-
bit model (stage III).
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bone. Defects were randomly allocated to one of the fol-
lowing experimental conditions: (1) rabbit autologous ASC
encapsulated in GGMA hydrogel (GGMA1 rASC); (2) micro-
fracture (MFX) (positive control) and iii) empty lesion
(negative control). Autologous rabbit ASC were encapsu-
lated in GGMA hydrogels as described earlier (10 3 106
cells/mL, 2% w/V) immediately before delivery into the
chondral defect. In situ crosslinking was promoted with
PBS and a setting time of 10 min was allowed before clo-
sure. MFXs were made with a 0.8-mm Kirshner wire (six
holes per defect) with 1- to 2-mm depth from which
bleeding was observed. Finally, the patella was reduced
and the wound was closed. After recovery from surgery,
animals were placed in individual cages and fed ad
libitum.
Assessment of in vivo cartilage tissue repair. Cartilage
regeneration was allowed for 8 weeks, after which animals
were anesthetized as described earlier and euthanized
(Eutasil, 200 mg/kg). In each knee, an internal para-patellar
incision was made and the patella carefully dislocated. Mac-
roscopic pictures were taken and explant tissue was har-
vested with a 6-mm diameter punch in order to collect
native tissue surrounding the lesion site, as well as sub-
chondral bone. Explants were parafﬁn-processed after ﬁxa-
tion (10% formalin) and decalciﬁcation (Biodec R, Bio-
Optica, Italy). For IHC, sections were processed as described
above, followed by incubation with primary antibody mouse
anti-rabbit anti-collagen I (Abcam, UK) or mouse anti-rabbit
anti-collagen II (Merck Millipore, USA) for 1 h, RT. Histo-
chemical staining of GAGs was performed by Safranin O/fast
green and three scoring systems were used to assess the
quality of cartilage repair, namely O’Driscoll, Pineda and
Wakitani.34
Statistical analysis
Results are summarized by mean or median and corre-
sponding standard deviation or interquartile range. For in
vitro studies, Student’s t test and two-way analysis of var-
iance (ANOVA) were used to evaluate differences among
groups. Normality was evaluated by the Shapiro-Wilk test.
When normality or homogeneity of variances was not veri-
ﬁed, non-parametric tests were used. For in vivo studies, the
histological scores for each specimen were evaluated inde-
pendently by three observers at three different times. For
evaluation, the observers were blinded for the type of treat-
ment and the specimens were randomly allocated to each
observer. The comparisons between treatment groups were
performed by two-way ANOVA. Since there were no statisti-
cal differences between the observers’ evaluations, the
results were analyzed using one-way ANOVA. In cases
where homogeneity of variances was not observed, the
Kruskal-Wallis nonparametric test was adopted. Multiple
comparisons were based on the Tukey HSD test or the
Mann-Whitney test, with the corresponding signiﬁcance
level and Bonferroni correction. Statistical analysis was per-
formed using the GraphPad Prism 4.0c software or IBM
SPSS Statistics, version 23. Statistical signiﬁcance was
deﬁned for p< 0.05.
RESULTS
In vitro chondrogenesis
Trilineage differentiation capacity was conﬁrmed for
CD731/CD901/CD1051/CD31–/CD34–/CD45– hASC, with
expressive mineralization, lipid formation, and GAG deposi-
tion upon osteogenesis, adipogenesis and chondrogenesis,
respectively [Fig. 2(a)]. Upon encapsulation within GG-
based hydrogel formulations, higher metabolic activity was
observed for hASC encapsulated in GGMA 1 and 2% w/V
as compared with GG at 1% w/V (p<0.01 and 0.001,
respectively) [Fig. 2(b)]. GG at 2% w/V provided inad-
equate sol-gel transition time for cell encapsulation studies.
After 7 days of culture, highest metabolic activity was
observed by cells encapsulated in GGMA 2% w/V
(p<0.01) therefore this formulation was selected for fur-
ther in vitro cell encapsulation studies concurrently with
GG 1% w/V (Fig. 3).
After 21 days of in vitro culture, the viability of chondro-
cytes and hASC, assessed microscopically by live/dead assay,
was comparable between GGp and GGMA hydrogels [Fig.
3(a), top and middle rows]. On the other hand, hASC chon-
drogenically differentiated within both hydrogel groups
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FIGURE 2. Preliminary in vitro studies with hASC. (a) Trilineage differentiation of hASC identified by alizarin red, oil red O and alcian blue stain-
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(hASC-chondro) demonstrated increased viability within the
GGMA hydrogel [Fig. 3(a), bottom row]. On what regards
expression of chondrogenic markers, both formulations
favored maintenance of healthy chondrocytes as evidenced
by signiﬁcantly increased expression of collagen type II rela-
tive to collagen type I. Such response was superior by the
GGMA formulation (p< 0.0001) as compared with the GG
(p< 0.001). Furthermore, chondrocytes cultured within the
GGMA hydrogel presented higher collagen type II expression
ratio as compared with the parent GGp hydrogel [Fig. 3(b),
top] (p<0.0001). On what regards hASC [Fig. 3(b), bottom],
such cells effectively expressed collagen type II upon chon-
drogenic stimuli (21 days) when cultured within either
hydrogel formulation (p> 0.05). Concurrently, collagen type
I expression was not superior to collagen type II at this
time-point (p> 0.05). When doubling hASC concentration
within the GGMA hydrogel up to 10 3 106 cells/mL,
increasing expression of collagen type II was obtained in
the course of chondrogenic differentiation [Fig. 4(a)]. Simul-
taneously, very low expression of collagen type I was
obtained along culture (p< 0.001 and 0.05 at days 14 and
21, respectively). Samples were further collected for histo-
logical analysis and subsequent identiﬁcation of extracellu-
lar matrix (ECM) components [Fig. 4(b)]. Progressive
deposition of healthy chondrogenic ECM was observed as
evidenced by safranin O/fast green staining of cartilage
matrix, alcian blue detection of sulfated GAG and IHC of
human collagen type II. The absence of collagen type I dep-
osition also indicates development of non-ﬁbrous cartilagi-
nous tissue. Macroscopically, transparent hydrogels at the
beginning of culture showed reduction in transparency (not
quantiﬁed) into an off-white opaque appearance after 3
weeks in vitro culture [Fig. 4(b), bottom row].
In vivo cartilage repair
At surgical treatment day, expanded rASC were mixed with
GGMA solution at time of surgery so as to form a homoge-
nous suspension. Upon injection into the lesion, the viscos-
ity of the suspension allowed spatial control of delivery
within the lesion volume, without spill over at the edges of
the defect. Geliﬁcation was allowed to occur during 10 min
as to assure maintenance of the hydrogel in the lesion site,
allowing immediate retention of cells in situ. Rabbits
remained healthy during all experimentation period, pre-
senting normal weight gain and absence of signs of infection
or disease. From macroscopic observation at time of explant
surgery, no apparent abnormalities of the patella position
were observed; neither signs of inﬂammation, abnormalities
of the synovium, loose bodies, osteophytes or degenerative
process were found. Macroscopic observation showed native
cartilage near the defect site as well as the opposing carti-
lage to be bright and white without visible degenerative
signs. In all defects, tissue formation was observed (Fig. 5),
and the margin between the defect and the surrounding car-
tilage were visible, which was more evident for the empty
control group. The defects treated with the GGMA1 rASC
combination showed compact bright tissue ﬁlling, despite
macroscopic variability observed between defects. The
lesions treated by MFX presented an irregular ﬁlling of the
lesion site, with tissue of a dim appearance. A similar out-
come was observed for untreated lesions (empty defects).
Tissue explants were further harvested for histological anal-
ysis. The quality of cartilage repair was assessed by three
scoring systems (Fig. 5), which have inverse scales for indi-
cation of cartilage quality and outcome: according to O’Dris-
coll, high point values indicate enhanced cartilage while
according to Pineda and Wakitani, low total point values
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represents superior repair. Inter observer differences were
assessed and no statistical differences were observed.
Immunolocalization of rabbit collagen type II and collagen
type I (Fig. 5) was performed to further characterize
cartilage formed within the lesion site. Treatment of chon-
dral lesions with GGMA1 rASC (Fig. 5, top) allowed restora-
tion of cartilage thickness, integration/bonding with native
cartilage, as well as intense and reasonably homogenous
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staining of ECM throughout the lesion site. Quantitative
assessment of repair by all three scoring systems indicates
signiﬁcant improvement in cartilage repair as compared
with the untreated lesions (p< 0.001). According to the
O’Driscoll score, GGMA1 rASC treatment also outperformed
MFX (p<0.05). Lesions treated with MFX (Fig. 5, Middle)
demonstrated overgrowth of the subchondral bone into the
lesion site which was covered by a thin layer of cartilagi-
nous matrix stained by safranin O and collagen type II. This
layer is irregular and bonding with adjacent native cartilage
is incomplete. Nevertheless, the extent of cartilage repair by
MFX was superior to untreated lesions, independently of the
scoring system used (p< 0.05). The bottom image repre-
sents histological assessment of untreated lesions, whereas
overgrowth of subchondral bone was evident and covered
by a thin regular tissue. Herein, very limited cartilaginous
matrix was formed, as indicated by the lack of safranin O/
fast green and reduced collagen type II staining at the top
layer of the tissue. Collagen type I deposition was negligible
in all groups, yet expressed slightly higher in the untreated
defects.
DISCUSSION
GG polysaccharide offers attractive features and characteris-
tics for this particular application due to its aqueous solubil-
ity and viscous properties at physiological temperature,
which makes it appealing for implementation of cell combi-
nation and surgical implantation protocols. In addition, the
crosslinking by physiological ions leads to formation of a
stable 3D structure and subsequent cell retention. In this
regard, functionalization of the GG molecule by methacryla-
tion extends solubility, allows control of spatiotemporal
crosslinking, which combined extends ﬂexibility of combina-
tion and implantation procedures and ﬁne-tuning of hydro-
gel stiffness. For instance, at 2% w/V, GGMA presents
increased storage modulus as compared with the unmodi-
ﬁed polysaccharide, 89.567.4 and 56.26 1.4 kPa, respec-
tively.22 Matrix stiffness, as a result of increased
concentration or biochemical cues, has been reported to
inﬂuence stem cell fate and particularly chondrogenesis.35
Within the context of this study, cells cultured within the
GGMA 2% w/V hydrogel shown improved cell metabolic
activity, viability, and healthy expression of chondrogenic
markers as compared with the least concentrated (1% w/V)
or non-functionalized matrix.
PoC in the rabbit model allowed evaluation of the carti-
lage repair potential of the GGMA 2% w/V hydrogel as com-
pared with MFX treatment. Currently considered as a gold-
standard treatment, MFX still has limitations on what con-
cerns the quality of the regenerated tissue, which can ulti-
mately lead to treatment failure upon recurrence of
symptoms.36,37 In this study, MFX group outcome showed
formation of a thin layer of chondral tissue concurrent with
subchondral bone overgrowth and an irregular surface.
Such repair outcome is likely to disfavor adequate load
bearing as well as smooth, pain-free joint motion.14,38,39 A
different outcome was observed for lesions treated with
GGMA–rASC—cartilage thickness was maintained equiva-
lently to adjacent native tissue while avoiding bone over-
growth. A smooth chondral surface was obtained following
this treatment and ECM staining demonstrated reasonably
uniform distribution of collagen type II and GAGs (Fig. 5).
This repair outcome is believed to support long-term qual-
ity of the tissue as opposed to MFX treatment. At the 8-
week time-point, statistical differences were obtained
between these groups according to O’Driscoll scoring.
Nevertheless, it is important to mention that quantitative
scores with a broad numerical range such as the O’Driscoll
system may increase the likelihood of ﬁnding statistically
signiﬁcant differences.34 Still, the adoption of O’Driscoll
score in the context of this study is pertinent as, contrary
to alternative scores, it assesses integration of the repair tis-
sue with its surroundings.34 In this study, no additional ﬁxa-
tion technique was used to retain the hydrogel within the
lesion site and precise volume ﬁlling was achieved, avoiding
the need for on-site shaping of the scaffolding structure,
which could be an advantage as compared with other cell-
based and tissue engineered cartilage products currently in
clinical development.12 In addition, viscous and sol-gel tran-
sition properties of the tested GGMA 2% w/V hydrogel
allowed controlled delivery of the matrix containing autolo-
gous ASC,14 directly to lesion site, which favored delivery
and retention of cells in situ. This fact is of signiﬁcant
importance as cell retention at lesion site is one of the
main indicators of success for lesion repair.12,40 Adoption of
the rabbit animal model for cartilage repair studies has sig-
niﬁcant advantages due to availability, ease of handling, low
cost and abundance of comparative literature,14,41 but poses
challenges related to reduced thickness (0.460.1 mm in
the trochlear groove) and surface area of articular cartilage.
This model is adequate for PoC studies during early stage
development of new technologies, particularly on what con-
cerns evaluation of ﬁxation of implantable devices.32,33 In
this regard, the ﬁxation merits of GGMA–rASC combination
was demonstrated in a particularly challenging environ-
ment. Heterogeneous outcomes were naturally observed yet
bona ﬁde chondral repair was obtained with this treatment
group, which is attributed to GGMA–rASC combination
alone. The analysis of non-treated lesions demonstrated a
limited self-healing of the induced defect that was statisti-
cally inferior than GGMA–rASC treatment. The self-repair
ability of cartilage lesions, which is commonly reported in
the rabbit model42,43 has been minimized by implementa-
tion of chondral defects with critical-size for which penetra-
tion and damage to the subchondral bone plate was
avoided.
The GGMA formulation successfully supported in vitro
chondrogenesis of both mature and progenitor cartilage-
forming cells. In a rabbit model, controlled delivery of cells
into chondral lesions was achieved, while adequate spatio-
temporal crosslinking supported volumetric ﬁlling of carti-
lage lesions and in situ retention of cells. Following 8 weeks
of treatment, the combination of GGMA–rASC, supported full
thickness regeneration of critical size lesions, good integra-
tion/bonding with native cartilage. Such combination
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therapy exhibited highly favorable physicochemical charac-
teristics and good biological performance which may sup-
port less invasive and complex surgical procedures for
cartilage repair.
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